RxDoctor Payments Data
★ My doctorsLook up a doctor →

Judy Wang, MD

Medical Oncology · Sarasota, FLNPI 1053554717

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $44,165 of the $64,473 with a category attached, or 68.5%. AstraZeneca accounts for 71.8% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2021 at $30,050 and has fallen 97.1% since, to $864 in 2025.

$64,473in general payments, 2019–2025

Across 452 payments — averaging $142.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$46K
  • Eisai Inc.$8K
  • Stemline Therapeutics Inc.$3K
  • Merck$759
  • Lilly USA, LLC$531
  • E.r. Squibb & Sons, L.L.C.$456
  • plus $5K from 54 others
$9,775,431in research payments, 2019–2025

Across 2,390 payments — averaging $4090.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$2.1M
  • Beigene, Ltd.$1.4M
  • GSK$1.3M
  • Astellas Pharma Inc$947K
  • AstraZeneca$511K
  • Beigene USA, Inc.$385K
  • plus $3.1M from 26 others

What the payments were for

  • Consulting fees$7,52512%
  • Speaking & faculty fees$44,16569%
  • Travel & lodging$3,6276%
  • Food & beverage$9,15714%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)80$46,306
Eisai Inc.15$7,755
Stemline Therapeutics Inc.2$3,360
Merck13$759
Lilly USA, LLC30$531
E.r. Squibb & Sons, L.L.C.27$456
Daiichi Sankyo Inc.13$367
Johnson & Johnson(2 entities)26$365
Seagen Inc.23$333
Incyte Corporation18$302
Bristol Myers Squibb17$283
Array Biopharma Inc14$254
Pfizer16$227
AbbVie11$225
Sanofi11$178
Abbott1$174
Heron Therapeutics, Inc.3$160
Gilead(2 entities)8$154
Novartis5$144
Astellas Pharma US Inc7$131
Covidien LP1$125
Pharmacyclics LLC, An Abbvie Company6$125
Amgen8$121
Jazz Pharmaceuticals Inc.8$115
Mirati Therapeutics, Inc.5$104
GSK5$102
Beigene USA, Inc.5$86
Exelixis Inc.6$84
Takeda Pharmaceuticals U.S.A., Inc.3$84
Foundation Medicine, Inc.1$78
Bayer5$68
Karyopharm Therapeutics Inc.4$61
Puma Biotechnology, Inc.4$57
Genentech USA, Inc.4$55
Regeneron Healthcare Solutions, Inc.3$50
Sumitomo Pharma America, Inc.3$49
EMD Serono, Inc.3$49
Dova Pharmaceuticals3$49
Adaptive Biotechnologies Corporation1$47
Taiho Oncology, Inc.3$45
Deciphera Pharmaceuticals Inc.2$40
Springworks Therapeutics, Inc.1$32
TG Therapeutics, Inc.2$30
GT Medical Technologies, Inc1$29
Clovis Oncology, Inc.3$28
Myovant Sciences Inc.2$24
Sirtex Medical Inc2$22
Kyowa Kirin, Inc.1$18
Sobi, Inc1$17
Pharmaessentia USA Corporation1$17
Rigel Pharmaceuticals, Inc.1$16
Legend Biotech USA Inc.1$16
Servier Pharmaceuticals LLC1$16
GE HealthCare1$16
Agios Pharmaceuticals, Inc.1$14
AVEO Pharmaceuticals, Inc.1$14
Immunomedics, Inc.1$14
Sanofi-aventis U.S. LLC1$14
G1 Therapeutics, Inc.1$13
Epizyme, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,473 in reported general payments places this provider in the 85th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$217,727
Medicare patients
156
Services billed
24,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexamethasone19$411
Prochlorperazine Maleate23$301
Ondansetron OdtOndansetron17$237
Gabapentin15$210
Methylprednisolone30$186
Morphine Sulfate ErMorphine Sulfate11$149
Oxycodone Hcl12$125
Prednisone27$106
Levothyroxine Sodium15$75

Paid to pharmacies, not to this prescriber.

Other medical oncology in Sarasota

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →